Breaking News, Financial News

Financial Report: Charles River 3Q10

RMS segment sales were $159.3 million in the quarter (-3%) and PCS segment sales were down 13% to $116.8 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River 3Q10 3Q Revenues: $276.1 million (-7%) 3Q Loss: $25.2 million (earnings were $37.0 million in 3Q09) YTD Revenues: $865.5 million (-5%) YTD Earnings: $5.9 million (earnings were $95.5 million YTD09) Comments: RMS segment sales were $159.3 million in the quarter (-3%) and PCS segment sales were down 13% to $116.8 million. In response to the continuing decline in demand for services, the company is reducing its headcount by approximately 4%, reducing discretionary spend...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters